Mortality in rheumatoid disease.
This paper provides an overview of rheumatoid disease from the perspective of its impact on mortality. The term, rheumatoid arthritis, may promote the misconception that this disease is relatively trivial and easily managed; therefore, "rheumatoid disease" is preferred. Numerous long-term studies in many settings have established that significant excess mortality is associated with rheumatoid disease, and that this excess mortality is related to cardiovascular disease deaths. Inflammation in rheumatoid and cardiovascular diseases shares the same biologic mechanisms. Severity of extraarticular disease, decline in functional level, and level of inflammatory activity are associated with increased risk of mortality. Detection and measurement of novel inflammatory biomarkers may provide tools to assess prognosis and to monitor therapy. Close attention to the management of traditional cardiovascular risk factors is essential in these patients. Whether disease modifying antirheumatic drug (DMARD) therapy will reduce all-cause and cardiovascular disease mortality in rheumatoid disease is the subject of ongoing studies.
Finch
William R
WR
Education and Research Service, Carl T. Hayden VA Medical Center, Phoenix, AZ 85012, USA. William.Finch@med.va.gov
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000191:economics / Q000401:mortality; D015415:Biomarkers; D006801:Humans; D015994:Incidence; D007249:Inflammation / Q000503:physiopathology; D011379:Prognosis; D012216:Rheumatic Diseases / Q000188:drug therapy / Q000191:economics / Q000401:mortality*; D012307:Risk Factors; D016019:Survival Analysis
D015415:Biomarkers